Objective: To estimate the impact on cardiovascular events of changes in high density lipoprotein (HDL) adjusted for changes in total cholesterol.
Design: Cohort study based on a record linkage database.
Setting: Community study in Tayside, Scotland, UK.
Patients: 18 815 patients were identified for the study between 1989 and 2001.
Main outcome measures: Cardiovascular events.
Results: 5510 patients taking lipid lowering treatment who had not been hospitalised previously for cardiovascular disease had 314 cardiovascular events recorded (9407 person years of follow up). Patients whose HDL rose by > 20% were less likely to have an event (23.5/1000 person years, 95% confidence interval (CI) 17.3 to 29.6) compared with patients whose HDL did not rise (42.6/1000 person years, 95% CI 35.5 to 49.7, adjusted relative risk 0.60, 95% CI 0.44 to 0.83). HDL change and cardiovascular outcome were not significantly associated among patients who had been hospitalised previously for cardiovascular disease or among patients who were not taking lipid lowering drugs.
Conclusion: In this study a rise in HDL independently predicted reduced cardiovascular risk in patients taking lipid lowering treatment who had not been hospitalised previously for cardiovascular disease.
- CHD, coronary heart disease
- HDL, high density lipoprotein
- ICD, International classification of diseases
- SMR01, Scottish Morbidity Record
- VA-HIT, Veterans Affairs high density lipoprotein cholesterol intervention trial
- high density lipoprotein change
- lipid lowering drug
- cardiovascular event
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Published Online First 10 October 2005
Conflicts of interest: TMM has received honoraria for lectures and advisory boards from Pfizer, Novartis, and Sankyo. MJM has received honoraria for lectures and advisory boards from AstraZeneca, Bristol Myers Squibb, Fournier, Novartis, and Pfizer.